IRMD — IRadimed Corporation

Summary of IRadimed Corporation Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: $22 million, a 13% increase from $19.5 million in Q1 2025.
• Operating Income: $7.2 million, up 33% year-over-year.
• Net Income: $5.8 million, or $0.45 per diluted share, a 22% increase from the previous year.
• Gross Profit: $16.8 million with a Gross Margin of 77%, slightly up from 76% in Q1 2025.
• Cash Flow from Operations: $8.3 million, a 93% increase compared to $4.3 million in Q1 2025.
• Cash and Cash Equivalents: $56.4 million at the end of the quarter.
• Dividend: A quarterly cash dividend of $0.20 per share declared, payable on May 29, 2026.

2. Strategic Updates and Business Highlights:

• Strong performance driven by the MRI-compatible IV infusion pump and MRI patient monitoring systems, particularly the new 3870 pump.
• The 3870 pump is showing a higher average selling price (ASP) than anticipated, with initial orders reflecting a 20% increase over the previous model.
• More than half of the orders for the new pump are for Quad systems, indicating a shift from dual-channel to four-channel systems, which enhances customer capacity.
• The company is focused on replacing an aging installed base of 3860 pumps, with a target to add 1,000 replacement channels annually.
• The sales team is experiencing high demand and customer interest in the new pump, leading to a positive outlook for future bookings.

3. Forward Guidance and Outlook:

• Q2 2026 Revenue Guidance: Expected between $20 million and $21 million, with GAAP diluted EPS of $0.40 to $0.44.
• Full Year 2026 Guidance: Revenue projected between $91 million and $96 million, with GAAP diluted EPS of $1.90 to $2.05.
• The company anticipates a controlled ramp-up in revenue, with significant growth expected in the latter half of 2026 as production of the 3870 pump increases.

4. Bad News, Challenges, or Points of Concern:

• Revenue from the older 3860 pump system is expected to decline, which may offset some of the growth from the new 3870 system in the short term.
• The company is being cautious in ramping up production of the 3870 pump to ensure quality and stabilize the supply chain, which may limit immediate revenue growth.
• The effective tax rate for the quarter increased due to timing of deductions, although it is expected to normalize by year-end.

5. Notable Q&A Insights:

• The shift to Quad systems is attributed to customer experiences where additional channels were needed, and the sales team effectively demonstrated the benefits of the new pump design.
• There is no financial incentive for customers to order four systems at once; rather, the higher ASP reflects the value of the new technology.
• The company is prioritizing existing customer orders over new greenfield opportunities, indicating a strong focus on replacing outdated equipment before expanding into new markets.
• Manufacturing capacity is being cautiously scaled, with plans to increase output significantly in the third and fourth quarters of 2026.

Overall, IRadimed's Q1 2026 results reflect strong growth driven by innovative product offerings, with a positive outlook for the remainder of the year despite some challenges related to transitioning from older products.